Patients from 22+ countriesPlan your visit →
lutetium-therapy
Patient Journey · 30 Jul 2026

PSA Flare After First Lu-177 PSMA Injection Explained

A rising PSA after your first Lu-177 PSMA injection may be a temporary flare, not treatment failure. Learn what causes it, how your oncology team distinguishes it from true disease progression, and when to call your doctor without delay.

Editorial oversight by Arpan Talwar·Founder, Art of Healing CancerUpdated 30 Jul 2026
PSA Flare After First Lu-177 PSMA Injection Explained

PSA Flare After First Lu-177 PSMA Injection Explained

This article is for patients with metastatic castration-resistant prostate cancer (mCRPC) who have received their first cycle of lutetium Lu-177 vipivotide tetraxetan (also known as Pluvicto) and now see a PSA number higher than before the injection.

You felt hopeful going in. Then the blood results came back higher than expected. Now you are wondering if the treatment has failed. That confusion is common.

Here is what you need to know: a rising PSA in the weeks after your first Lu-177 PSMA injection does not always mean the therapy is failing. It might be a PSA flare - a temporary rise that happens as radiation kills cancer cells. This article explains what a PSA flare is, why it occurs, how your care team tells it from true disease progression, and when you should call your doctor.

What Is a PSA Flare?

PSA stands for prostate-specific antigen. Prostate cells, including cancer cells, make this protein. Normally, a rising PSA means cancer is growing. But that is not always true - especially in the first weeks after starting a new therapy.

A PSA flare is a temporary rise in PSA that appears shortly after treatment begins. It does not last. After the initial spike, PSA levels come back down - often below where they started. The pattern looks like a short climb then a fall, not a steady climb upward.

A published review of the flare phenomenon in prostate cancer across several treatment types notes that clinicians and patients should know about this effect. It prevents stopping a treatment that may be working. The review notes that rising PSA in the early weeks of therapy, without worsening on imaging or symptoms, does not mean treatment is failing.

Why Does PSA Rise After Lu-177 PSMA Therapy?

When lutetium Lu-177 vipivotide tetraxetan binds to PSMA receptors on prostate cancer cells, it delivers targeted beta radiation directly to them. The radiation kills cancer cells. As the cells die, they release their contents - including stored PSA - into the bloodstream.

This causes a flood of PSA from dying cells. Your blood test picks this up as a rise. In this case, the rise does not mean new cancer appeared. It means the cancer that was already there is breaking down from the therapy.

This is the same mechanism for PSA flare seen with other prostate cancer treatments like docetaxel chemotherapy and radium-223 bone-targeting radiation. Cancer cells die, PSA leaks out, and the blood test captures it before it clears.

Not all early PSA rises after Lu-177 PSMA therapy are flares. Some rises do show true progression. Your oncology team makes this distinction using the full picture - not just one blood test result.

How Common Are PSA Fluctuations During Radioligand Therapy?

Exact flare rates for Lu-177 PSMA therapy are still being studied. Research shows that PSA fluctuations during radioligand therapy are common. They do not mean the same thing as a sustained rise.

A study of mCRPC patients receiving radioligand therapy found that patients with PSA fluctuations during treatment had comparable survival outcomes to those with a sustained PSA decrease. This is meaningful. A PSA reading that goes up between cycles, especially if it is not steadily climbing, does not automatically show the therapy is failing.

Research on early PSA changes after the first cycle of Lu-177 PSMA shows that biochemical measurements around four weeks after the first injection can hint at longer-term response. But researchers caution against stopping therapy after just one cycle based on PSA alone, because some patients who respond slowly still improve in later cycles.

For comparison, PSA flare has been documented in studies of radium-223, another targeted radiation for bone-metastatic prostate cancer. In one study, patients treated with radium-223 showed a PSA rise after the first cycle followed by a later fall. Their survival was comparable to patients who had an early PSA drop. The same principle applies to Lu-177 PSMA - do not read one early rise as failure.

Flare or True Progression: How Your Team Tells the Difference

Your care team will use several pieces of information together. Here is what each one looks like in practice.

Timing

A PSA flare most often appears in the first four to twelve weeks after the first treatment. If your PSA rose in that window, a flare is one explanation your team will consider. A PSA that starts rising many months into treatment - after it had already been falling - is more likely to show true progression.

Pattern Across Multiple Readings

Your team will not act on a single PSA reading. They compare values over time. A flare shows a rise followed by a fall. True progression shows a pattern of sustained rise across multiple consecutive measurements.

The Prostate Cancer Working Group (PCWG3) defines PSA progression as a rise of at least 25% from the lowest PSA recorded during treatment, with an absolute increase of at least 2 ng/mL, confirmed by a second test taken at least three weeks later. This confirm-before-acting rule exists because one abnormal reading can mislead. Your clinical team applies similar thinking even outside a formal trial setting.

Imaging Findings

A PSMA-PET scan gives a much more direct picture of what is happening inside the body. True disease progression usually shows new lesions, growing lesions, or new areas of PSMA uptake. A PSA flare does not produce those changes - scans may look stable or improved while the blood test looks alarming.

If your imaging looks stable or better while your PSA rose, that combination strongly supports a flare rather than progression. To understand more about why imaging is so central to monitoring response, read our guide on how Lu-177 PSMA works through PSMA targeting and theranostics.

Your Symptoms

Are your symptoms better, the same, or clearly worse? True disease progression typically brings worsening symptoms - new bone pain, pain in new areas, or a drop in daily function. A PSA flare often happens without worsening symptoms, or alongside a brief and settling discomfort.

A pain flare is a related phenomenon - a temporary worsening of bone pain shortly after treatment. It differs from a PSA flare, though both can happen near the same time. Our article on the pain flare after Lu-177 PSMA therapy explains what to expect and how to manage it.

What to Do While You Wait for the Pattern to Clear

Waiting between cycles when your PSA rose is one of the harder parts of this treatment. It is normal to feel anxious. Here are a few things that can help.

  • Keep a symptom log. Write down each day whether pain, energy, and general comfort are better, the same, or worse compared to before the injection.
  • Track your PSA readings in one place over time so you can see the trend, not just the latest number.
  • Ask your nurse or patient navigator what to watch for and when to call between appointments.
  • Resist interpreting a single blood test in isolation. Ask your team for context at every visit.

Sleep disruption is common when a blood result causes worry between appointments. If you are having trouble sleeping since your PSA rose, talk to your doctor about what might help. Always check with your oncologist before adding any supplement or herbal product to your routine.

The most important instruction is this: do not stop Lu-177 PSMA treatment on your own based on a blood result. Your team must decide whether to continue, pause, or change therapy, using the full picture - PSA trend, imaging, blood counts, kidney function, and symptoms together. No single number should drive that decision.

When to Call Your Doctor Between Appointments

Most PSA rises after the first cycle can wait for a scheduled review. But some situations call for earlier contact. Reach out to your oncology team without delay if a rising PSA is accompanied by any of the following:

  • New bone pain or worsening pain in areas that were stable before treatment
  • Neurological changes - weakness in the legs, changes in bladder or bowel control, or numbness in the lower body, which may suggest spinal cord involvement
  • Fever, chills, or any sign of infection
  • A PSA that doubles rapidly at multiple consecutive measurements with no signs of slowing
  • A sharp drop in your ability to manage daily activities

In these situations your team will likely bring imaging forward or review your case before the next scheduled cycle. This is not a reason to panic - it is a reason not to delay.

What Your Team Will Review Before Your Next Cycle

Before each subsequent cycle of Lu-177 PSMA therapy, your oncology team typically reviews your PSA trend, a full blood count, kidney and liver function tests, and a clinical check of your symptoms. Your team may also order imaging if the PSA pattern or your symptoms suggest it.

If your PSA has started to fall from its peak - even if it is still above your starting level - that is meaningful. It suggests the flare is resolving and therapy may be working. If the PSA is still rising and imaging shows new activity, your team will discuss whether to continue the current plan or consider alternatives.

Our article on what to monitor after your Lu-177 PSMA cycles and how to build a follow-up care plan walks through the full monitoring schedule across the treatment course.

If you are being treated abroad and cannot quickly reach your treating team to help interpret a PSA result between cycles, the Art of Healing Cancer nuclear-medicine team can review your blood results and imaging remotely - so you do not have to wait alone for an answer.

PSA Is One Tool Among Several

PSA is useful, but it is an imperfect marker. It can rise for reasons unrelated to cancer growth - including urinary tract infection, recent urological examination, or inflammation from treatment itself. It can also drop even if the cancer has not responded.

PSMA-PET imaging now gives a much more direct view of whether cancer cells are taking up the therapy. Many nuclear medicine specialists place more weight on imaging findings than on PSA alone in the weeks right after the first cycle, precisely because of the possibility of a flare. Your team is already tracking multiple signals together. A rising PSA is one data point in a larger picture.

Ask after every appointment: "What does the full picture show, not just the PSA?" This leads to a more accurate conversation about how the therapy is working.

When to Talk to Your Doctor

If your PSA rose after your first injection, share that result and any symptom changes with your oncology team at your next appointment. If you develop new bone pain, neurological symptoms, or fever alongside a rising PSA, call without waiting for a scheduled visit. Do not stop treatment on your own based on a single blood result. If you want an independent review of your PSA pattern and scan findings, or a broader second opinion on whether Lu-177 PSMA therapy remains right for you, you can submit your details through the Lutetium Therapy contact form. If Lu-177 is not the best next step for your situation, the review can also discuss alternative options you might consider.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.

Frequently asked questions

Is a rising PSA after my first Lu-177 PSMA injection always a sign that treatment is failing?

Not necessarily. A PSA rise in the first weeks after your first injection can be a PSA flare - a temporary increase caused by PSA released from cancer cells being damaged by the radiation. This is different from true disease progression. Your oncology team will not make a decision based on a single blood test. They look at the trend across multiple readings, compare it with imaging results, and consider how your symptoms are changing before drawing any conclusions.

How long does a PSA flare typically last after Lu-177 PSMA therapy?

Precise duration data specific to Lu-177 PSMA therapy is still being studied. Research on similar treatments suggests a PSA flare can last anywhere from a few weeks to a couple of months. Your team will track your PSA over multiple readings across the first two to three cycles to see whether it resolves on its own. If PSA is still rising past twelve weeks with no sign of leveling, your team will reassess using the full picture - imaging, symptoms, and blood results together - not just the blood test.

Should I stop Lu-177 PSMA treatment if my PSA went up after the first injection?

No - not on your own, and not based on a single reading. The decision to continue, pause, or change treatment involves your PSA trend over time, imaging results, blood counts, kidney function, and how you are feeling. Stopping early based on one reading could mean abandoning a therapy that may still show benefit over the full course. Always discuss concerns with your care team before making any change to your treatment plan.

What is the clinical definition of PSA progression during prostate cancer treatment?

The Prostate Cancer Working Group (PCWG3) defines PSA progression as a rise of at least 25% from the lowest PSA recorded during treatment, with an absolute increase of at least 2 ng/mL, confirmed by a second test taken at least three weeks later. This two-step confirmation rule exists to prevent a transient rise - such as a flare - from being misclassified as treatment failure. Your clinical team applies similar reasoning, though the exact criteria may vary slightly outside a formal trial setting.

Can my PSA keep rising for more than one cycle and still come down later?

Yes, this can happen. Some patients show a delayed response to Lu-177 PSMA therapy where PSA does not begin to fall until the second, third, or even fourth cycle. Research has found that patients with PSA fluctuations during radioligand therapy can have comparable overall outcomes to those who respond more quickly. This is one reason most specialists recommend completing at least two to three cycles before drawing firm conclusions about whether the therapy is working, unless imaging or symptoms give a clear reason to change course sooner.

Does a PSA flare mean the Lu-177 PSMA therapy is definitely working?

A PSA flare is consistent with the therapy having an effect on cancer cells - the rise may come from PSA released by cells that are being damaged. However, a flare is not a guarantee of a lasting response. Some patients experience a transient rise and the treatment still does not achieve a durable benefit. Your team watches for the broader pattern: whether PSA falls after the flare, whether imaging shows stable or improved findings, and whether symptoms are holding steady or getting better.

Have a specific question about your situation?

A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.

Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.

PSA Flare After Lu-177 PSMA: Flare vs. Progression | lutetium-therapy